The conversation discusses managing estradiol problems during finasteride treatment. Suggestions include stopping finasteride every 3 months for 2-3 weeks or reducing the dosage.
A user shared progress pictures 1.5 months after a hair transplant of 3500 grafts, using oral finasteride, topical finasteride, minoxidil, and vitamins. They are concerned about potential shock loss and the thinning appearance.
The user is asking about the difference between a dermaroller and a dermastamp for hair loss treatment, noting that the dermaroller tangles and pulls out hair. They are seeking advice on which tool is better for long hair.
A user shared progress pictures 12 months after a hair transplant and daily use of dutasteride. The conversation discusses the quality of comparison photos and the use of hair fibers.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
A user switched from a 1.5 mm derma roller to an adjustable dermastamp for microneedling to treat hair loss and found it less painful and more effective. Some users prefer different depths and tools like the Dr.Pen for microneedling, while others debate the necessity of depth and tool type.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
The conversation is about a hair loss product that claims to use stem cells and ingredients like Capixyl, Redensyl, and Baicapil, with the user asking if anyone has looked into it. No specific treatments were discussed.
A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.
The conversation discusses feelings of despair and low self-worth due to hair loss and other perceived physical shortcomings. The user expresses a lack of motivation and struggles with societal expectations, despite trying various self-improvement methods.
Hair loss is causing distress and self-esteem issues, with discussions on treatments like finasteride, minoxidil, and hair transplants. Some suggest topical treatments or lifestyle changes, while others stress the importance of confidence and self-acceptance.
Stem cell hair transplants are not FDA approved and remain theoretical, with concerns about effectiveness and safety. Current treatments like finasteride and minoxidil are still the main options, while hair cloning and new drug cures are likely years away.
A user shared their successful 1-year update after a 2300 FUE hair transplant in Seoul, Korea, praising Dr. Ko's work for achieving a natural-looking hairline. The conversation includes admiration for the results and inquiries about the procedure's cost and requirements.
The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
The conversation is about recommending safe and effective dermaroller or dermastamp brands for hair loss treatment. Users discuss avoiding cheap options to prevent scalp damage and share usage frequency.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.
A user inquired about Hair XL offered by a clinic in the Netherlands, questioning if it is a form of Exosome treatment. The conversation seeks experiences and clarity on the treatment.
Trans woman experiences hair thinning despite low testosterone and treatments like finasteride and microneedling. Possible causes discussed include past eating disorder and current stack of medications and supplements.
The conversation is about a user's progress with hair loss treatment using 0.5mg oral finasteride and 50ml of Essegen-F topical finasteride daily, with improved hair density and minimal side effects. The user also used ketoconazole shampoo for seborrheic dermatitis and noticed significant hair regrowth over 1.5 years.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
The conversation discusses the use of Verteporfin in hair loss treatment. It suggests that Verteporfin could potentially regenerate hair follicles instead of forming scars, providing an unlimited donor supply for hair transplants.
The conversation discusses preventing infection from derma stamping for hair loss treatment, with suggestions to reduce needle depth and consider alternatives like tretinoin. The user experienced irritation possibly from zinc chloride and stopped using the shampoo and derma stamping.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
The user shared progress on hair regrowth using oral dutasteride, oral minoxidil, and verteporfin procedures. They reported some regrowth after 6-9 months of treatment.
The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.